27
Klinisk strålebiologi - normalvev

Klinisk strålebiologi - normalvev

Embed Size (px)

DESCRIPTION

Klinisk strålebiologi - normalvev. Tidlig reaksjon. Sen reaksjon. teleangiectasi. Basis for dose-respons-kurver. Stigetallet for dose-responskurven. Gaussian distribution of radiation sensitivity. Gaussian distribution of technical and dosimetrical factors. - PowerPoint PPT Presentation

Citation preview

Page 1: Klinisk strålebiologi  -  normalvev

Klinisk strålebiologi - normalvev

Page 2: Klinisk strålebiologi  -  normalvev
Page 3: Klinisk strålebiologi  -  normalvev

Tidlig reaksjon

Page 4: Klinisk strålebiologi  -  normalvev

teleangiectasi

Sen reaksjon

Page 5: Klinisk strålebiologi  -  normalvev
Page 6: Klinisk strålebiologi  -  normalvev
Page 7: Klinisk strålebiologi  -  normalvev

Basis for dose-respons-kurver

Page 8: Klinisk strålebiologi  -  normalvev

Stigetallet for dose-responskurven

Page 9: Klinisk strålebiologi  -  normalvev
Page 10: Klinisk strålebiologi  -  normalvev

Gaussian distribution of radiation sensitivity

Dose response curve

Uniquely described by two parameters: - gradient at 50% response

levelD50% - dose to achieve 50%

response

Gaussian distribution of technical and dosimetrical

factors

biolo > clin Pettersen M et al Radiotherapy and Oncology 2008

Clinical dose response curve

Page 11: Klinisk strålebiologi  -  normalvev

Uniquely described by two parameters: - gradient at 50% response

levelD50% - dose to achieve 50%

response

is linked to the standard deviation, , of the Gaussian distribution by:

21

Pettersen M et al Radiotherapy and Oncology 2008

22bioldoseclin ),( bioldoseclin f and ),( bioldoseclin f

Page 12: Klinisk strålebiologi  -  normalvev

Steepness of clinical dose-response curve is depending of the dose variation

Pettersen M et al Radiotherapy and Oncology 2008

Roué et al 2004ESTRO-Equal external audit102 centres, 235 beams in France3% beams had deviations > 5%24 centres had deviations > 5%

Page 13: Klinisk strålebiologi  -  normalvev

Design of a randomised clinical study

• The null hypothesis is that the two treatment options produce no different outcome

• To prove a difference, the null hypothesis has to be rejected

• The number of patients needed is linked to , the difference in response (R), the level of significance () and the power ()

= 0.2 = 0.05

Pettersen M et al Radiotherapy and Oncology 2008

Page 14: Klinisk strålebiologi  -  normalvev

The number of patients required

Conclusions:To keep the number of patients

required for RCT as low as possible, the standard deviation of the

dosimetry should be kept below 5%.

Page 15: Klinisk strålebiologi  -  normalvev
Page 16: Klinisk strålebiologi  -  normalvev
Page 17: Klinisk strålebiologi  -  normalvev
Page 18: Klinisk strålebiologi  -  normalvev
Page 19: Klinisk strålebiologi  -  normalvev
Page 20: Klinisk strålebiologi  -  normalvev

Volumeffet for rektumblødning

Page 21: Klinisk strålebiologi  -  normalvev

Strandqvist plot

Page 22: Klinisk strålebiologi  -  normalvev
Page 23: Klinisk strålebiologi  -  normalvev
Page 24: Klinisk strålebiologi  -  normalvev

-kill

-kill

LQ-formelverket

Page 25: Klinisk strålebiologi  -  normalvev
Page 26: Klinisk strålebiologi  -  normalvev
Page 27: Klinisk strålebiologi  -  normalvev